TY - JOUR
T1 - New findings in osteoarthritis pathogenesis
T2 - Therapeutic implications
AU - Pulsatelli, Lia
AU - Addimanda, Olga
AU - Brusi, Veronica
AU - Pavloska, Branka
AU - Meliconi, Riccardo
PY - 2013
Y1 - 2013
N2 - This review focuses on the new perspectives which can provide insight into the crucial pathways that drive cartilage-bone physiopathology. In particular, we discuss the critical signaling and effector molecules that can activate cellular and molecular processes in both cartilage and bone cells and which may be relevant in cross talk among joint compartments: growth factors (bone morphogenetic proteins and transforming growth factor), hypoxia-related factors, cell-matrix interactions [discoidin domain receptor 2 (DDR2) and syndecan 4], signaling molecules [WNT, Hedgehog (Hh)]. With the continuous progression of our knowledge on the molecular pathways involved in cartilage and bone changes in osteoarthritis (OA), an increasing number of potentially effective candidates for OA therapy are already under scrutiny in clinical trials to ascertain their possible safe use in an attempt to identify molecules active in slowing or halting OA progression and reducing joint pain. We then review the principal molecules currently under clinical investigation.
AB - This review focuses on the new perspectives which can provide insight into the crucial pathways that drive cartilage-bone physiopathology. In particular, we discuss the critical signaling and effector molecules that can activate cellular and molecular processes in both cartilage and bone cells and which may be relevant in cross talk among joint compartments: growth factors (bone morphogenetic proteins and transforming growth factor), hypoxia-related factors, cell-matrix interactions [discoidin domain receptor 2 (DDR2) and syndecan 4], signaling molecules [WNT, Hedgehog (Hh)]. With the continuous progression of our knowledge on the molecular pathways involved in cartilage and bone changes in osteoarthritis (OA), an increasing number of potentially effective candidates for OA therapy are already under scrutiny in clinical trials to ascertain their possible safe use in an attempt to identify molecules active in slowing or halting OA progression and reducing joint pain. We then review the principal molecules currently under clinical investigation.
KW - Articular cartilage
KW - New treatments
KW - Osteoarthritis
KW - Signaling pathways
UR - http://www.scopus.com/inward/record.url?scp=84875665620&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875665620&partnerID=8YFLogxK
U2 - 10.1177/2040622312462734
DO - 10.1177/2040622312462734
M3 - Article
C2 - 23342245
AN - SCOPUS:84875665620
VL - 4
SP - 23
EP - 43
JO - Therapeutic Advances in Chronic Disease
JF - Therapeutic Advances in Chronic Disease
SN - 2040-6223
IS - 1
ER -